Matthew S. Davids, MD, MMSc

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Peter Hillmen ;

Marco Montillo ;

Florence Cymbalista ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Matthew S. Davids , MD, MMSc;

Ian W. Flinn ;

Julio Delgado ;

Bryone J. Kuss ;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Peter Hillmen ;

Julio Delgado ;

Marco Montillo ;

Bryone J. Kuss ;

Florence Cymbalista ;

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Matthew S. Davids , MD, MMSc;

10/23/2019

An improved benefit‐risk profile of duvelisib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received 2 prior therapies

Purpose of the Study: Despite effective frontline therapies, many patients with CLL or SLL eventually relapse and require additional therapies to control their disease. Duvelisib, a ...

Hagop Youssoufian ;

Ian W. Flinn ;

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Ulrich Jager ;

Paolo Ghia ;

Stephan Stilgenbauer ;

Peter Hillmen ;

Marco Montillo ;

Florence Cymbalista ;

David T. Weaver ;

Matthew S. Davids , MD, MMSc;

Stephanie Lustgarten ;

10/23/2019

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial

Purpose of the Study: Duvelisib, a first-in-class oral dual PI3K-, inhibitor, was approved by the FDA for treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/smal...

Julio Delgado ;

Bryone J. Kuss ;

Constantine S. Tam ;

Francesc Bosch ;

Ulrich Jager ;

Paolo Ghia ;

Florence Cymalista ;

Stephan Stilgenbauer ;

Fritz Offner ;

David T. Weaver ;

Stephanie Lustgarten ;

Hagop Youssoufian ;

Ian W. Flinn ;

Nicole Lamanna ;

Marco Montilo ;

Matthew S. Davids , MD, MMSc;

Gabriel Etienne ;

10/22/2019

Research Reports

The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia in the United States: A Cost of Care and Budget Impact Model of Venetoclax Plus Obinutuzumab Sequences

06/21/2022

Matthew S. Davids , MD, MMSc;

Mazyar Shadman , MD, MPH;

Beenish S. Manzoor , PhD, MPH;

Kavita Sail , PhD;

Arliene Ravelo , MPH;

Fang Han ;

Sheila Shapouri , MS;

Nisha C. Hazra , PhD, MSc;

Annie Guerin , MS;

Honghao Fang , MSc;

Dr Davids and colleagues estimated the total cumulative costs per patient of treatment sequences for adults with chronic lymphocytic leukemia, with and without deletion 17p, as well as the budget impact of introducing sequences with...

Dr Davids and colleagues...

06/21/2022

Journal of Clinical Pathways

Venetoclax resistance: Mechanisms and treatment options

Matthew S. Davids , MD, MMSc;

10/25/2019

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown ;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

10/23/2019

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown ;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

10/23/2019